Business
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
Company to host conference call and webcast on Thursday, November 2, 2023, at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc.
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\nCompany to host conference call and webcast on Thursday, November 2, 2023, at 4:30 p.m. Eastern Time\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Thursday, November 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.\n\n\nThe conference call will be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until December 4, 2023. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.\n\n\nAbout Acadia Pharmaceuticals\n\n\nAcadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231019859462/en/\n\nMedia Contact:\nAcadia Pharmaceuticals Inc.\nDeb Kazenelson\n(818) 395-3043\[email protected]\n\n\nInvestor Contact:\nAcadia Pharmaceuticals Inc.\nAl Kildani\n(858) 261-2872\[email protected]\n\n\nAcadia Pharmaceuticals Inc.\nJessica Tieszen\n(858) 261-2950\[email protected]\n\n\nSource: Acadia Pharmaceuticals Inc.","length":4768,"tagName":"div"}]